11th INTERNATIONAL SYMPOSIUM ON PEDIATRIC NEURO-ONCOLOGY

THE WESTIN COPLEY PLACE, BOSTON, MASSACHUSETTS

June 13–16, 2004

 

PROGRAM SCHEDULE AND ROOM ASSIGNMENTS

 

 

Sunday, June 13, 2004

 

12:00pm-7:00pm  REGISTRATION                                                                                                                  (America Foyer –4th Floor)

                                                                                                                                               

2:30-2:40pm          WELCOME ADDRESS                                                                                                      (America North - 4th Floor)

                                                      Peter Black, Mark Kieran, Archie Bleyer and Roger Packer

 

2:40-4:00 pm         NEW THERAPEUTICS FORUM                                                                                        (America North - 4th Floor)

                                                      Chairs – Mark W. Kieran and Peter Phillips

 

        2:40         Phillips               Overview of novel chemotherapy targets  

        2:50                 Bio 37         Anti-medulloblastoma effects of valproic acid as a histone deacetylase inhibitor; Xiao-Nan Li et al. Houston, TX

        3:00                 Bio 20         Conditionally replicating adenoviruses expressing P53 or targeted towards EGFR exhibit enhanced oncolytic potency in malignant gliomas; Birgit Geoerger et al. Villejuif, France

        3:10                 Bio 45         Glutathione S-Transferase (GST) polymorphisms and outcomes in central nervous system (CNS) tumors in childhood and adolescents; M. Fatih Okcu et al. Houston, TX

        3:20         Kieran                 Overview of biologic targets                        

        3:30                 Bio 34         Species specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an anti-angiogenesis mechanism; Walter E. Laug et al. Los Angles, CA

        3:40                 Exp 08        Do medulloblastomas samples meet the FDA criteria for anti-Erbb2 therapy with Trastuzumab?; N. Entz-Werle et al, Villejuif, France

        3:50                 Bio 50         ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor inhibits growth of multiple primary central nervous system tumor types; Jeremy N. Rich et al. Durham, NC

 

4:00-5:55 pm         EPIDEMIOLOGY OF PEDIATRIC BRAIN TUMORS                                                       (America North - 4th Floor)

                                                      Chairs – Archie Bleyer and Faye Davis

                                                                                                                                

        4:00         Bleyer                  Introduction

        4:05                 Epi 02         Older adolescents and young adults with brain tumors in the United States:  Lack of clinical trial participation and of survival prolongation and mortality reduction; Archie Bleyer et al. Houston, TX

        4:15                 Epi 40         Paediatric Neuro-oncology from 2500 BC to now, an historical perspective; David Walker et al; Nottingham, UK

        4:35                 Epi 01         CNS tumor epidemiology & outcome in adolescents and young adults in the United States, 1975-1998; Anne Bendel et al.  Minneapolis, MN

        4:45                 Epi 15         The pre-diagnostic problems in children with primary brain tumors; Monika Drogosiewicz et al. Warsaw, Poland

        4:55                 Epi 31         Expression of survival in medulloblastoma: Collins’ Law revisited - Toronto experience (1986 -2003); M. Ronghe et al, Toronto, Canada

        5:05                 Epi 07         Outcome of treatment induced high-grade glioma (HGG) in children: A study of the Canadian Pediatric Brain Tumour Consortium; Anne-Sophie Carret et al. Montreal, Canada

        5:15                 Epi 13         Childhood cancer registry in Argentina (Registro Oncopediatrico Hospitalario Argentino: ROHA) primary tumour cases; Blanca Diez et al. Buenos Aires, Argentina

        5:25         Davis                   Introduction to the international pediatric neuro-oncology epidemiology core

        5:30                 Epi 45         Biologic and environmental risk factors for childhood brain tumors:  the California Childhood Brain Tumor Study; Paul Fisher et al. Palo Alto, CA

                                                                                                                                

6:00-7:30 pm         WELCOME RECEPTION                                                                                         (Staffordshire Room – 3rd Floor)

     

                                                     

Monday, June 14, 2004

                                                                                                                                                               

7:00am-5:30pm    REGISTRATION                                                                                                                  (America Foyer –4th Floor)

       

7:00-8:30am          CONTINENTAL BREAKFAST                                                                                            (America Foyer –4th Floor)

 

8:00-9:30am          BIOLOGY OF MEDULLOBLASTOMA                                                                              (America Center & South)

                                                      Chairs – Richard Gilbertson, Tobey MacDonald, and Scott Pomeroy

         

        8:00                 Bio 07         Autofluorecent mouse models of human medulloblastoma; Christopher Calabrese et al. Memphis, TN

        8:10                 Bio 21         Transcription factors expressed by neural crest cells correlate with phenotype in development and in neuroectodermal tumors; Timothy Gershon et al. New York, NY

        8:20                 Bio 14         PDGFR inhibition in medulloblastoma cells induces apoptosis and alters gene expression; Tobey MacDonald et al. Washington, DC

        8:30                 Bio 08         Transgenic mouse model of Erb-B2 over-expression in cerebellar granule neuron precursor cells; Christopher Calabrese et al. Memphis, TN

        8:40                 Bio 09         Identification of tumour suppressor genes in childhood medulloblastoma by promoter hypermethylation profiling; Steven Clifford et al. Newcastle-upon-Tyne, UK                    

        8:50                 Bio 15         Combined histopathological and molecular cytogenetic stratification defines a high-risk subset of patients with medulloblastoma – A United Kingdom Children's Cancer Group Study; David W. Ellison et al. Newcastle-upon-Tyne, UK

        9:00                 Bio 60         Molecular genomics of medulloblastoma; Hai Yan et al. Durham, NC

        9:10                 Bio 36         A novel and rapid approach to protein expression profiling of cerebrospinal fluid (CSF) from medulloblastoma patients using functionalizied magnetic beads, AnchorchipTM  technology, Maldi-TOF and Maldi-TOF/TOF mass spectrometry; S.M. Leung et al. Billerica, MA

        9:20         Pomeroy             Summary of the biology of medulloblastoma

 

8:00-9:30am          NURSING UPDATE – PART I                                                                                               (Essex South - 3rd Floor)

                                                      Chairs – Christine Chordas, Kristen Graham and Mary Ann Lefrancois                                                          

        8:00         Lefrancois          Introduction and session goals

        8:05         McGuire Cullen Translational nursing in pediatric neuro-oncology: Bench to bedside

 

        8:35                 Out 12         Paediatric oncology health information on the internet: a survey of usage by families; Darren Hargrave et al. Toronto, Canada

        8:45                 LE 28          Influence of postoperative active feeding in body weight of children with posterior fossa tumours; Laura Powell et al. Birmingham, UK

        8:55                 Epi 28         End-of-life care of children with central nervous system (CNS) tumours; Darren Hargrave et al. Toronto, Canada

        9:05                                      Panel discussion of abstracts

        9:10         Lefrancois          Experimental therapies

        9:25                                      Discussion and closing

 

9:30-10:30am        STANDARD-RISK MEDULLOBLASTOMA FORUM                                                       (America Center & South)

                                                      Chairs – Roger Packer and Giorgio Perilongo

                                                                                          

        9:30         Packer                Overview of standard-risk medulloblastoma

        9:45                 Epi 43         Desmoplastic versus non-desmoplastic medullobastoma: differences in clinical outcome?; Stergios Zacharoulis et al. Boston, MA             

        9:55                 Imag 03      Results of central imaging review for patients enrolled on average risk medulloblastoma (MB) Protocol A9961; Amar Gajjar et al. Memphis, TN

        10:05               Ther 61       Preliminary report of A9961: A phase III randomized study of craniospinal radiotherapy (CSRT) followed by one of two adjuvant chemotherapy regimens (CCNU, CPDD, VCR or CPM, CPDD, VCR) in children with newly diagnosed average-risk medulloblastoma (MB); Roger Packer et al. Washington, DC

        10:15               Ther 11       Is there justification for the continued use of vincristine in pediatric brain tumor treatment?; Ken Cohen et al. Baltimore, MD

        10:25      Perilongo           Discussion of standard-risk medulloblastoma

 

10:35-11:00am     BREAK                                                                                                                                 (America Foyer –4th Floor)

 

11:00am-12:30pm                    HIGH-RISK MEDULLOBLASTOMA/PNET FORUM                                    (America Center & South)

                                                      Chairs – David Ashley and Eric Bouffet

                                                                                                                                

        11:00      Ashley                 Background for the therapy of high-risk medulloblastoma/ PNET                                                     

        11:15               Ther 78       Outcome for patients with Chang stage M2-3 medulloblastoma (MB) treated with SIOP/UKCSSG PNET-3 chemotherapy (CT); Roger Taylor et al. Leicester, UK

        11:25               Ther 81       Treatment of high-risk medulloblastomas in children above the age of 3 years: the SFOP TC 04/94 study; Joris Verlooy et al. Paris, France

        11:35               Ther 25       Excellent event-free survival (EFS) in newly diagnosed high risk (HR) medulloblastoma (MB) treated with craniospinal radiation (CSI) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue: results of a prospective multi-center trial (SJMB96); Amar Gajjar et al. Memphis, TN

        12:45               Ther 40       Pilot study of reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy consisting of thiotepa and melphalan in children with M1/2/3 medulloblastoma; Junichi Hara et al. Osaka, Japan 

        11:55               Ther 28       Myeloablative chemotherapy with peripheral blood stem cell rescue before craniospinal radiotherapy in patients with medulloblastoma with post-operative residual or metastatic disease.  Results of a mono-institutional study in Italy; Maria Luisa Garre et al, Genoa, Italy

        12:05      Bouffet                Summary of therapeutic approaches for high-risk medulloblastoma/ PNET                              

                                                                                          

       

12:30-2:00pm        LUNCH AND POSTER VIEWING                                                                 (Posters in America North - 4th Floor)

                                                      Box Lunch will be provided

 

2:00-3:00pm          RELAPSED MEDULLOBLASTOMA/PNET FORUM                                                       (America Center & South)

                                                      Chairs – Didier Frappaz and Antony Michalski

                                                     

        2:00                 Ther 65       A UKCCSG study of the treatment of relapsed CNS primitive neuroectodermal tumours using high dose chemotherapy; Susan Picton et al. UK

        2:10                 Ther 05       Results of the HIT-REZ-97 study: treatment of relapsed primitive neuroectodermal brain tumors (PNET) in childhood and adolescents; Udo Bode et al. Bonn, Germany

        2:20                 Ther 21       A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem cell rescue in resistant or recurrent pediatric brain tumors; Nick Foreman et al. Denver, CO

        2:30                 Ther 26       Phase I dose escalation of temozolomide with thiotepa and carboplatin with autologous stem cell rescue (ASCR) in patients with recurrent/refractory central nervous system (CNS) tumors; Sharon Gardner et al. New York, NY

        2:40                 Ther 17       High-dose carboplatin, thiotepa and etoposide with autologous stem cell rescue (ASCR) for recurrent medulloblastoma; Ira Dunkel et al. New York, NY

        2:50         Frappaz              Summary of stem cell transplantation for the treatment of relapsed medulloblastoma/ PNET

                                                                                                                                                                                                                               

3:00-4:00pm          MINIMALLY INVASIVE/ INNOVATIVE TECHNIQUES IN NEUROSURGERY                (America Center & South)

                                                      Chairs – Peter Black, Liliana Goumnerova

                                                                                          

        3:00         Black                   Intraoperative MRI Surgery For Children With Brain Tumors                                                               

        3:15                 Epi 37         Craniotomy for resection of pediatric brain tumors in the United States 1988-2000: provider volume – outcome relationships and effects of progressive centralization and specialization of care; Ed Smith et al. Boston, MA

        3:25                 Imag 10      Combined stereotactic positron emission tomography and magnetic resonance imaging for image-guided surgical resection of brain tumors in children; Benoit Pirotte et al. Brussels, Belgium

        3:35                 Exp 10        Feasibility of radiosurgery for malignant brain tumors using robotic radiosurgery; Cole A. Giller et al. Dallas, TX

        3:45         Goumnerova     Endoscopic procedures in pediatric CNS tumors

 

3:00-4:00pm          CURRENT TOPICS IN NEUROFIBROMATOSIS                                                               (Essex South - 3rd Floor)

                                                      Chairs – Roger Packer and Brigitte Widemann

                                                     

        3:00         Widemann         Current clinical trials in neurofibromatosis type I

        3:20                 Imag 06      Usefulness of proton magnetic resonance spectroscopy (MRS) in differentiation of pathologic lesions in neurofibromatosis type 1 (NF-1) in children; Elzbieta Jurkiewicz et al. Warsaw, Poland

        3:30                 Bio 44         Neurofibromatosis 3: a report of patients meeting diagnostic criteria for both neurofibromatosis 1 and 2; Bryan C. Oh et al. Los Angeles, CA

        3:40         Packer                Current topics and future directions in neurofibromatosis therapy

 

4:00-4:30pm          BREAK                                                                                                                                (America Foyer –4th Floor)

                                

4:30-6:30pm          QUALITY OF LIFE FORUM                                                                                                  (Essex South - 3rd Floor)

                                                      Chairs – David Osoba and Susan Parsons

                                                     

        4:30         Parsons             Welcome

        4:35         Osoba                 Lessons from using QOL instruments in adults

        5:00         Parsons             The Development of CNS Specific Pediatric QOL Instruments

        5:25                 Out 07         Use of a verbal language screening tool prior to pediatric quality of life (QOL) questionnaire administration; Patricia Garvie et al. Memphis, TN

        5:35                 Out 19         Quality of Life Assessment (QUOLA) in pediatric brain tumor population: feasibility and measurement properties of a new brain-specific instrument.  May Lin Tao et al. Los Angeles, CA

        5:45                 Out 23         Development of a quality of life scale for children with chronic illness with CNS involvement:  preliminary data; Pamela Wolters et al. Bethesda, MD

        5:55                 Out 05         Searching for a tool to assess quality of life (QOL) in brain tumour survivors – results of the PEDQOL in a cohort of Italian children and adolescents; Cinzia Cereda et al.  Padova, Italy

        6:05                 Out 17         Health-related quality of life of children with brain tumors:  parent report using the HUI2/3; Eugene Meyer et al. Boston, MA 

        6:15         Parsons             Questions And Discussion                         

 

4:30-5:30pm          LEPTOMENINGEAL DISEASE FORUM                                                                            (America Center & South)

                                                      Chair –Susan Blaney

                                

        4:30         Blaney                 Experimental agents for intrathecal use

        4:50                 Exp 09        Estimating CSF topotecan exposure in children with high-risk meduloblastoma and supratentorial primitive neuroectodermal tumor (PNET) using a pharmacokinetic model; Burgess B. Freeman III et al. Memphis, TN

        5:00                 Exp 03        Experiences with intraventricular etoposide in neoplastic meningitis of relapsed metastatic brain tumors; Udo Bode et al. Bonn, Germany

        5:10                 Bio 05         Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter 211AT-labeled thymidine analogue; Abraham Boskovitz et al. Durham, NC

        5:20                 Exp 12        Intrathecal 131-I-labeled 3F8 antibody in patients with GD2-expressing central nervous system and leptomeningeal neoplasms; Kim Kramer et al. New York, NY                     

                                                                                                                                                                                                                                               

5:30-6:30pm          CURRENT ADVANCES IN NEURORADIOLOGY                                                             (America Center & South)

                                                      Chairs – Gilbert Vizena, Tina Young-Poussaint and Robert Zimmerman

       

        5:30         Zimmerman      Magnetic Resonance Imaging and Spectroscopy in Pediatric CNS Tumors

        5:50                 Imag 02      White matter lesions (WML) detected by magnetic resonance imaging (MRI) following radiation therapy (RT) and high dose chemotherapy (HDC) in children with medulloblastoma (MB) and supratentorial PNET (SPNET); Maryam Fouladi et al. Memphis, TN

        6:00                 Imag 21      Single photon emission tomography (SPECT) findings in children with and without posterior fossa syndrome after cerebellar tumor resection; M. Zwienenberg-Lee et al. Rotterdam, Netherlands

        6:10                 Imag 09      Mobile lipids detected by short echo time 1H magnetic resonance spectroscopy correlate with malignancy in childhood brain tumors; Andrew Peet et al. Birmingham, UK

        6:20                 Imag 20      Analysis of correlative mri perfusion and diffusion in a phase I Trial of the anti-angiogenesis agent SU5416 in children with refractory or progressive brain tumors: a report from the Pediatric Brain Tumor Consortium (PBTC); Tina Young-Poussaint et al. Boston, MA           

                                                                                                                                

6:30pm                   DINNER  (on your own)

                                                                                                                                

7:00pm                   NURSING RECEPTION & DINNER                                                                                       (Essex North– 3rd Floor)

 

 

Tuesday, June 15, 2004

 

7:00am-5:30pm    REGISTRATION                                                                                                                 (America Foyer –4th Floor)

                                

7:00-8:30am          CONTINENTAL BREAKFAST                                                                                           (America Foyer –4th Floor)

 

8:00-9:30am          OUTCOMES & SURVIVORSHIP – PART I: NEUROPSYCHOLOGY                              (Essex South - 3rd Floor)

                                                      Chair - Raymond Mulhern                           

                                                     

        8:00         Mulhern              Overview of neurocognitive outcomes in survivors of pediatric CNS malignancies                       

        8:20                 Out 11         Preliminary evidence of nonverbal learning disability in survivors of pediatric brain tumors; Kristina Hardy et al. Durham, NC

        8:30                 Out 18         Subtests profile of Wechsler Intelligence Scales in patients with pineal germ cell tumors; Ryo Nishikawa et al. Saitama, Japan

        8:40                 LE 02          Longitudinal neuropsychological study of children with medulloblastoma; Joanne Ater et al. Houston, TX

        8:50                 LE 22          The effect of radiation dosimetry on IG after conformal radiation therapy in pediatric patients with localized ependymoma; Thomas Merchant et al. Memphis, TN

        9:00                 Out 21         Neuropsychological bases of everyday cognitive problems in adolescents treated for craniopharyngioma; Deborah Waber et al. Boston, MA

        9:10                 LE 23          Age at diagnosis. A prominent risk factor when evaluating cognitive performance following risk-adapted treatment for medulloblastoma; Shawna Palmer et al. Memphis, TN  

        9:20                                      Discussion               

 

8:00-9:30am          BIOLOGY OF PEDIATRIC CNS TUMORS                                                                        (America Center & South)

                                                      Chairs – Peter Black, Ian Pollack and Josh Rubin

                                                     

        8:00         Black                   Applications for neural stem cells in the treatment of CNS tumors                                                   

8:15         Rubin                  Molecular basis for CXCR4 dependent glioma growth

       

        8:25                 Bio 02         The hypoxia inducible cell death gene BNIP3 is mutated in malignant astrocytic tumors; David D Eisenstat et al. Winnipeg, MB Canada

        8:35                 Bio 23         Inhibition of receptor tyrosine kinases and mammalian target of rapamycin offers combinatorial benefit in tumor control; Jeremy N Rich et al. Durham, NC

        8:45                 Bio 28         SB-431542, a small molecule transforming growth factor-b-receptor antagonist, inhibits human glioma cell line proliferation and motility; Jeremy N Rich et al. Durham, NC 

        8:55                 Exp 13        Potential role of thymosin-A1 adjuvant therapy for glioblastoma; Peter Manley et al. Providence, RI

        9:05                 Bio 13         Genomic imbalances in high and low-grade paediatric astrocytomas; Richard Grundy et al. Birmingham, UK

        9:15         Pollack                Immuno-therapeutic strategies for malignant gliomas

                                                                                                                                                                                                                               

9:30-11:00              OUTCOMES & SURVIVORSHIP – PART II: MULTIDISCIPLINARY CARE                    (Essex South - 3rd Floor)

                                                      Chair – Christopher Turner

                                                                                          

        9:30         Turner                 Overview of medical late effects and approaches to multidisciplinary care of survivors of CNS tumors

        9:50                 LE 07          Functional outcome of children < 4 years of age with CNS malignancies; Elizabeth Gilger et al. Memphis, TN    

        10:00               Ther 48       Effect of neo-adjuvant chemotherapy on long-term health state and behavior in the PNET3 RCT of treatment for primitive neuro-ectodermal tumour (PNET); Colin Kennedy et al, Southampton, UK

        10:10               LE 30          Medical sequelae of pediatric low grade glioma; Antoinette Schouten-van Meeteren et al. Amsterdam, The Netherlands.

        10:20               LE 12          Incidence and trends of overweight and at risk for overweight among pediatric central nervous system (CNS) tumor patients; Della Howell et al. Atlanta, GA

        10:30               LE 20          Protection by hypothyroidism due to craniospinal irradiation in medulloblastoma patients; Maura Massimino et al. Milan, Italy

        10:40      Turner                 Summary and discussion                           

 

9:30-11:00am        HIGH-GRADE GLIOMA SESSION                                                                                     (America Center & South)

                                                      Chairs – Henry Friedman and Peter Phillips          

                                

        9:30         Phillips               Treatment strategies for malignant glial tumors                   

        9:45                 Ther 84       The impact of extent of surgical resection of consensus-reviewed pediatric intracranial high-grade glioma on outcome: a report of the Children’s Cancer Group trial no. CCG-945; Dermot M Murphy et al. Arcadia, CA

        9:55                 Ther 04       Long term outcome for children less than six years of age with diagnosis of consensus reviewed high-grade gliomas: a report of the CCG-945 study; Vandana Batra et al. Arcadia, CA

10:05               Ther 16       High-grade gliomas (HGG) in children below 5 years of age: results of a chemotherapy only approach with the BBSFOP protocol. A multicenter trial of the French Society of Pediatric Oncology; Christelle Dufour et al. France

 

        10:15      Friedman           Small molecule inhibitors in brain stem gliomas 

        10:30               Ther 31       Thalidomide and carboplatin for the treatment of brain stem glioma; Stewart Goldman et al. Chicago, IL

        10:40               Epi 03         Incidence and patterns of neuraxis metastasis (NM) in patients (pts) with diffuse pontine glioma (DPG); James Brashears et al. Durham, NC

        10:50               Exp 02        Topotecan as a radiosensitizer in the treatment of children with malignant brainstem gliomas: results of a SFOP phase II study, Valerie Bernier et al. France

                                                                                                                                                               

11:00-11:30am     BREAK                                                                                                                                (America Foyer –4th Floor)

                                                                                                                                                                                                                               

11:30am-1:00pm  KEYNOTE ADDRESS                                                                                                          (America Center & South)

                                                      ANGIOGENESIS INHIBITION AS A TARGET FOR CANCER THERAPY 

                                                                                           M. Judah Folkman

                                

1:00-2:30pm          LUNCH  AND POSTER VIEWING                                      (Posters in America North - 4th Floor)

                                                      (Lunch on your own)                                                                                                                                    

 

2:30-4:00pm          LOW-GRADE GLIOMA SESSION                                                                                    (America Center & South)

                                                      Chairs – Blanca Diez and Giorgio Perilongo          

                                                                                          

        2:30                 Bio 03         Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas; Ute Bartels et al. Toronto, Ontario, Canada

        2:40                 Epi 20         Predictors of tumor progression in pediatric gangliogliomas; Lynn Gargan et al. Dallas, TX

        2:50                 Epi 21         Disseminated juvenile pilocytic astrocytoma in childhood; Russ Geyer et al.  Seattle, WA

        3:00                 Ther 36       Phase II study of oral temozolomide (TMZ) in children with progressive low-grade gliomas (LGG); Sri Gururangan et al. Durham, NC

        3:10                 Bio 06         Gene expression profiling of progressive and stable childhood pilocytic astrocytomas; Daniel Bowers,et al. Dallas, TX

        3:20                 Ther 06       Pilot study of vinblastine in patients with recurrent and refractory low grade glioma; Eric Bouffet et al. Toronto, Canada

        3:30                 Ther 63       Age less than one year as prognostic factor for progression-free survival (PFS) in children affected by low grade glioma (LGG), initially treated with chemotherapy (CT); a report from the SIOP-LGG 1993 study; Giorgio Perilongo et al.  Padua, Italy

        3:40                 Ther 71       Temozolomide in the treatment of progressive low-grade glioma; Nasjla Saba et al. São Paulo, SP – Brazil.

        3:50         Diez                                                          Discussion               

 

4:00-5:00pm          CURRENT TREATMENTS FOR EPENDYMOMA                                                             (America Center & South)

                                                      Chairs – Stewart Goldman

       

        4:00                 Bio 18         P53 pathway dysfunction in primary childhood ependymomas and xenografts; Nathalie Gaspar et al. Villejuif, France

        4:10                 Bio 52         Integrative profling of chromosomal copy number abnormalities and gene expression in pediatric ependymomas; Michael Sheldon et al. Houston, TX

        4:20                 Ther 24       Ependymoma : current controversies; Didier Frappaz et al. Lyon, France

        4:30                 Epi 23         Intracranial childhood ependymomas: an analysis of prognostic patterns of failure in the group of 154 consecutive patients; Wieslawa Grajkowska et al. Warsaw, Poland

        4:40                 Ther 29       Childhood ependymoma:  improved survival for patients with incompletely resected tumors with the use of pre-irradiation chemotherapy; James Garvin et al. New York, NY

        4:50         Goldman            Discussion

 

 

5:30-10:00pm        GALA EVENT at FENWAY PARK (Home of the BOSTON RED SOX)

                                

 

       

Wednesday, June 16th, 2004

                                

7:00am-Noon        REGISTRATION                                                                                                                  (America Foyer –4th Floor)

 

7:00-8:30am          CONTINENTAL BREAKFAST                                                                                            (America Foyer –4th Floor)

                                                                                          

8:00-9:00am          NEUROPATHOLOGY UPDATE AND PLATFORM PRESENTATIONS                           (Essex South - 3rd Floor)

                                                      Chairs – Peter Burger, David Louis and Lucy Rorke                                                                             

 

        8:00                 Bio 22         What’s in a name? Floyd Giles et al. Los Angeles, CA

        8:15         Rorke                  Subependymal Giant Cell Astrocytomas (SEGAs)

        8:30         Burger                 Low-grade astrocytomas

        8:45         Louis                   1p/19q testing          

                                

8:00-9:00am          RADIATION ONCOLOGY UPDATE                                                                                   (America Center & South)

                                                      Chairs – Larry Kun, Karen Marcus and Nancy Tarbell

                                                                                                                                

        8:00                 Exp 11        Intraoperative radiation therapy with the photon radiosurgery system in children with recurrent brain tumors: a preliminary report; John Kalapurakal et al. Chicago, IL

        8:10                 Exp 17        Stereotactic fractionated conformal dynamic interstitial brachytherapy of intracranial germ cell tumors; Jinlin Wang et al. Shanghai, China

        8:20                 Ther 08       Reduction of cochlear dose using proton boost for pediatric medulloblastoma; Yen-Lin Chen et al. Boston, MA

        8:30         Panel                  Practicum in Radiation Oncology; Issues in the planning and treatment of ependymoma, medulloblastoma and craniopharyngioma

 

9:00-10:00am        CRANIOPHARYNGIOMA SESSION                                                                                  (America Center & South)

                                                      Chairs – Richard Hayward and R. Michael Scott                                                                                   

 

        9:00                 Ther 66       Childhood craniopharyngioma: classification and treatment according to the degree of hypothalamus involvement; S. Puget et al. Paris, France

        9:10                 Imag 15      Surveillance imaging following attempted curative treatment for childhood craniopharyngioma: how often and how long? Gurish Solanki et al. London, UK

        9:20                 Ther 43       Intracyctic bleomycin therapy for craniopharyngioma in children: Canadian experience; Juliette Hukin et al. Vancouver, Canada

        9:30                 LE 10          Outcome of craniopharyngioma in children: long-term complications and quality of life; Michael A Grotzer et al. Zurich, Switzerland

        9:40                                      Discussion               

 

10:00-10:30am     BREAK                                                                                                                                 (America Foyer –4th Floor)

       

10:30-11:30am     CURRENT APPROACHES TO GERM CELL TUMORS   (America Center & South)

                                                      Chairs – Jonathan Finlay and Masao Matsutani                                                                                    

 

        10:30      Matsutani           Introduction and overview of current approaches to CNS germ cell tumors                                    

        10:35               Ther 58       Multi-institutional cooperative clinical study for intracranial germ cell tumors in Japan; Masao Matsutani et al. Irumagun, Japan

        10:45               Epi 09         Male predominance in CNS germ cell tumors: analysis of SEER data; Paul Chuba et al. Detroit, MI

        10:55               Ther 02       Combined approach with ventricular irradiation for CNS germinoma: the SIOP European consensus. Claire Alapetite et al. Paris, France

        11:05               Ther 70       Multimodality therapy for CNS non-germinoma germ cell tumors (NGGCT): results of a phase II consortium; Patricia Robertson et al. Ann Arbor, MI

        11:15               Epi 32         Pattern of relapse after irradiation alone in localized intracranial germinoma; Frank Saran et al. Sutton, UK

        11:25      Finlay                  Summary and Discussion                          

 

10:30-11:30am     NURSING UPDATE - PART II                                                                                               (Essex South - 3rd Floor)

                                                      Chairs – Christine Chordas, Kristen Graham and Mary Ann Lefrancois

       

        10:30      Chordas             Welcome                   

        10:35      Chordas             Parent’s Perspectives of clinical Service needs of childhood brain tumor survivors

        10:45               Out 01         Survey of caregiver concerns in raising a child with a brain tumor; Heather Austin et al. Birmingham, AL

        10:55               LE 24          Osteopenia and health-related quality of life in survivors of brain tumors treated in childhood; Isaac Odame et al. Hamilton, Ontario, Canada

        11:05               Out 20         A school intervention program to address the learning and school adjustment needs of children treated for brain tumors; Maria Luisa Victoria et al. Boston, MA                

        11:15               Out 02         A group social skills intervention program for survivors of childhood brain tumours; Maru Barrera et al. Toronto, Canada

        11:25                                   Discussion

                                                                                                                                                                               

11:30am-12:30pm                    PHASE I CONSORTIUMS AND THERAPIES                                              (America Center & South)

                                                      Chairs – Howard Fine and Larry Kun                                                                                                       

                                                     

        11:30               Exp 04        Role of temozolomide (TMZ) following radiation therapy (RT) in the treatment of children with newly diagnosed diffuse brainstem glioma (BSG): results of a multi-institutional study (SJHG-98); Alberto Broniscer et al.  Memphis, TN

        11:40               Exp 15        Phase I study of concurrent cereport and carboplatin with radiation therapy for children with newly-diagnosed brain stem gliomas (BSG); Roger Packer et al. Washington, DC

        11:50               Ther 45       A phase I trial of temozolomide and CCNU in pediatric patients with newly diagnosed incompletely resected non-brainstem high-grade gliomas (HGG):  a Children's Oncology Group study; Reggie Jakacki et al.  Pittsburgh, PA

        12:00      Kadota                Overview and summary of current COG phase I studies

                                

        12:10      Fine                     Overview and summary of current NIH phase I studies

                                

        12:20      Kun                     Overview and summary of current PBTC phase I studies                                                                                   

 

12:30-2:00pm        LUNCH & POSTER TAKEDOWN TIME                                                      (Posters in America North - 4th Floor)

                                                      (Box Lunch Provided)                                                                                                                                   

 

2:00-3:30pm          CNS TUMORS IN INFANTS                                                                                               (America Center & South)

                                                      Chairs – David Ashley, Jonathan Finlay, Russ Geyer and Chantal Kalifa                                        

 

        2:00                 Ther 33       Localized medulloblastomas can be cured without recourse to craniospinal irradiation provided complete surgery can be carried out: final results of the first French prospective study in children below five years of age (BBSFOP); Jacques Grill et al. Villejuif, France

        2:10                 Ther 86       Efficacy of high dose cyclophosphamide with etoposide and vincristine (“Vetopec”) in very high risk paediatric brain tumours; Richard J. Cohn et al. Randwick, Australia

        2:20                 Ther 69       High dose chemotherapy and posterior fossa radiotherapy for children less than 3 - 5 years with localized high-risk medulloblastoma at diagnosis or at relapse. The SFOP experience. Vita Ridola et al. Paris, France

        2:30                 Ther 09       Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: response to “Head Start” induction chemotherapy intensified with high-dose methotrexate; Susan Chi et al. Boston, MA

        2:40                 Ther 87       Cure of children less than 3 years of age with medulloblastoma (M0/M1 stage) by post-operative chemotherapy only: final results of the HIT:SKK'92 study; Stefan Rutkowski et al. Wuerzburg, Germany

        2:50         Panel                  International round table discussion: Medulloblastoma/PNET and high-grade gliomas

 

3:30-4:00pm          BREAK                                                                                                                                 (America Foyer –4th Floor)                                                                               

4:00-5:30pm          CNS ATYPICAL TERATOID/RHABDOID TUMOR FORUM                                            (America Center & South)

                                                      Chairs - Jackie Biegel, Russ Geyer and Lucy Rorke            

 

        4:00         Rorke                  Overview of CNS atypical teratoid/rhabdoid tumors (AT/RT)               

        4:10         Biegel                 Genetics of AT/RT    

        4:20                 Epi 24         Registry for central nervous system (CNS) atypical teratoid tumor / rhabdoid tumor (AT/RT): treatment and outcome in 42 cases; Sharon Meerbaum et al.  Cleveland, OH

        4:30                 Ther 75       Outcome of therapy for atypical teratoid/rhabdoid tumors (AT/RT) on Pediatric Oncology Group study (POG) 9233/34; Douglas Strother et al. Calgary, Alberta, Canada

        4:40                 Ther 46       Atypical teratoid rhabdoid tumors (AT/RT) of the central nervous system (CNS): survival and treatment response in 35 patients diagnosed at Children’s Hospital of Philadelphia; Anna Janss et al. Philadelphia, PA

        4:50                 Exp 05        Phase II studies of antineoplastons A10 And AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system.  A preliminary report. Gabor Jurida et al. Houston, TX

        5:00         Geyer                  Review of AT/RT abstracts (Epi 05, Ther 03, Ther 13, Ther 27, Ther 30, Ther 32,Ther 38, Ther 50, Ther 59, Ther 64 and Ther 79)

        5:10         Panel                  Discussion 

 

5:30 pm                  MEETING ADJOURNS

 

 

--